Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

PURPOSE: AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine. We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients. EXPERIMENTAL DESIGN: In this Phase I study, patients received intravenous AZD77...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Chemother Pharmacol
Päätekijät: Sausville, Edward, LoRusso, Patricia, Carducci, Michael, Carter, Judith, Quinn, Mary F., Malburg, Lisa, Azad, Nilofer, Cosgrove, David, Knight, Richard, Barker, Peter, Zabludoff, Sonya, Agbo, Felix, Oakes, Patricia, Senderowicz, Adrian
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4486055/
https://ncbi.nlm.nih.gov/pubmed/24448638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2380-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia